Proscia, a Philadelphia, PA-based leader in digital and computational pathology solutions, has raised $37 million to advance the way we understand and treat diseases like cancer.
The round was led by Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital as well as existing investors including Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures. This investment brings Proscia's total funding to $72 million.
The financing will enable Proscia to accelerate the adoption of computational pathology, strengthening its market and product leadership. It will use the infusion of capital to scale its commercial operations. This includes expanding its sales, marketing
Company: Proscia Inc.
Round: Series C
Funding Month: June 2022
Lead Investors: Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital
Additional Investors: Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures.
Company Website: https://proscia.com/
Software Category: Concentriq® Digital Pathology Platform
About the Company: Led by CEO David West, Proscia is a software company that is accelerating pathology's digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 10 of the top 20 pharmaceutical companies rely on Proscia's software each day.